Efficacy and Safety of Desidustat Versus Erythropoietin in Post Kidney Transplant Anaemia: A Prospective Observational Study - PubMed

4 hours ago

Desidustat (HIF-PHI) and erythropoietin both significantly improved hemoglobin levels in kidney transplant recipients with anemia over 8 weeks.
No significant differences were found between desidustat and erythropoietin groups in hemoglobin improvement, inflammatory markers, or iron indices.
Both treatments were well-tolerated with no reported adverse events, highlighting their safety in short-term follow-up.
Oral administration of desidustat offers convenience, suggesting it as a patient-centered option for post-transplant anemia management.

Hasty Briefsbeta